CJC-1295 isn't stocked on pharmacy shelves in Polūr or anywhere else for that matter — this is a specialist compound distributed through a dedicated online market. The upside of this online-only market is that serious vendors are judged entirely by their analytical documentation, giving researchers better verification tools than local retail ever could. What consistently distinguishes top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for safety documentation. This guide takes Polūr researchers through that evaluation process and explains the signals that distinguish quality CJC-1295 suppliers.
What Studies Say About CJC-1295
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Polūr researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source CJC-1295 — Vendor Guide
Vetting CJC-1295 vendors starts with the COA: request the batch-specific certificate before purchasing, not after. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger serious immune reactions even at trace quantities. Warning signs in CJC-1295 vendor evaluation: prices significantly below market average, vague sourcing information, no community presence, and COAs that do not include endotoxin results. Hold lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order CJC-1295 — ships to Polūr
COA-verified · International tracking · Research grade
All use of CJC-1295 in Polūr or anywhere must be research use only — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; repeated freeze-thaw cycles of reconstituted material should be avoided by preparing small aliquots before storage. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results stated as EU/mg and compare against acceptable research limits for your application. For any individual considering CJC-1295 outside a formal research context: seek medical advice first — this compound is not a licensed human medication and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
